Medicine Gets Personal. / Marc Wortman.
by Wortman, Marc; Kinkead, Gwen; SIRS Publishing, Inc.
Material type:
BookSeries: SIRS Enduring Issues 2002Article 2Health. Publisher: Technology Review, 2001; Worth, 2001ISSN: 1522-323X;.Subject(s): Drugs -- Side effects | Genetic screening | Genetic disorders | Human gene mapping | Medical innovations | Pharmaceutical industry | PharmacogenomicsDDC classification: 050 Summary: MEDICINE GETS PERSONAL -- "This is an era of transition in medicine: from the time of 'one size fits all' drugs created for and marketed to all patients, to the emerging epoch of personalized medicines, in which drugs are geared to the specific genetic makeup of groups or individuals. This transition is causing growing pains for some companies. But the ultimate payoff, a decade or more away, should be enormously beneficial to patients, enabling doctors to think about stopping tumors before they begin and heart attacks before they happen." (TECHNOLOGY REVIEW) This article examines how pharmaceutical companies are preparing to spearhead a pharmacogenomics revolution upon completion of the Human Genome Project.Summary: GENOMICS GETS DOWN TO BUSINESS -- "The mapping of the Genome? Last year's miracle. New and old players in the drug industry are now staking out positions in the science of genotyping, which is on its way to giving us a powerful understanding of our genetic destiny and changing the face of medicine." (WORTH) This article examines the benefits and drawbacks of genotyping, a means of determining patients' potential reactions to medication or their susceptibility to disease.
| Item type | Current location | Call number | Status | Date due |
|---|---|---|---|---|
Books
|
High School - old - to delete | SIRS HEA2 2 (Browse shelf) | Available |
This MARC record contains two articles.
Articles Contained in SIRS Enduring Issues 2002.
Originally Published: Medicine Gets Personal, Jan./Feb. 2001; pp. 72+.
Originally Published: Genomics Gets Down to Business, June 2001; pp. 82+.
MEDICINE GETS PERSONAL -- "This is an era of transition in medicine: from the time of 'one size fits all' drugs created for and marketed to all patients, to the emerging epoch of personalized medicines, in which drugs are geared to the specific genetic makeup of groups or individuals. This transition is causing growing pains for some companies. But the ultimate payoff, a decade or more away, should be enormously beneficial to patients, enabling doctors to think about stopping tumors before they begin and heart attacks before they happen." (TECHNOLOGY REVIEW) This article examines how pharmaceutical companies are preparing to spearhead a pharmacogenomics revolution upon completion of the Human Genome Project.
GENOMICS GETS DOWN TO BUSINESS -- "The mapping of the Genome? Last year's miracle. New and old players in the drug industry are now staking out positions in the science of genotyping, which is on its way to giving us a powerful understanding of our genetic destiny and changing the face of medicine." (WORTH) This article examines the benefits and drawbacks of genotyping, a means of determining patients' potential reactions to medication or their susceptibility to disease.
Records created from non-MARC resource.
There are no comments for this item.